Skip to main content

Table 2 Univariate analysis of the characteristics associated with miliary TB among TB-IRIS

From: Prevalence and risk factors of paradoxical tuberculosis associated immune reconstitution inflammatory syndrome among HIV-infected patients in Beijing, China

Characteristics

Miliary TB (19) N (%)

Non-miliary TB (26) N (%)

Total (45) N (%)

Crude Orb (95% CI)

P value

Gender

 Male

18 (94.7)

24 (92.3)

42 (93.3)

1

Ref.

 Female

1 (5.3)

2 (7.7)

3 (6.7)

0.667 (0.056–7.937)

0.748

Age group (years)

  < 25

7 (36.8)

2 (7.7)

9 (20.0)

8.167 (1.412–47.221)

0.019

 25–44

9 (47.4)

21 (80.8)

30 (66.7)

1

Ref.

 45–64

3 (15.8)

2 (7.7)

5 (11.1)

3.500 (0.497–24.654)

0.208

  > 64

0 (0.0)

1 (3.8)

1 (2.2)

1

Initial CD4 cell count

  > 100

1 (5.3)

1 (3.8)

2 (4.4)

1

Ref.

 50–100

1 (5.3)

2 (7.7)

3 (6.7)

0.500 (0.013–19.562)

0.711

  < 50

17 (89.5)

23 (88.5)

40 (88.9)

0.739 (0.043–12.674)

0.835

CD4 cell count after ART

  > 100

6 (31.6)

15 (57.7)

21 (46.7)

1

Ref.

 50–100

8 (42.1)

8 (30.8)

16 (35.5)

2.500 (0.640–9.766)

0.188

  < 50

5 (26.3)

3 (11.5)

8 (17.8)

4.167 (0.749–23.179)

0.103

Increase in CD4 cell count

  < 4 folds

9 (47.4)

12 (46.2)

21 (46.7)

1

Ref.

  ≥ 4 folds

10 (52.6)

14 (53.8)

24 (53.3)

0.952 (0.291–3.117)

0.936

HIV virial load

  ≤ 1000 copies

10 (52.6)

14 (53.8)

24 (53.3)

1

Ref.

  > 1000 copies

9 (47.4)

12 (46.2)

21 (46.7)

1.050 (0.321–3.436)

0.936

HAART regimena

 First-line

15 (78.9)

23 (88.5)

38 (84.4)

1

Ref.

 Second-line

4 (21.1)

3 (11.5)

7 (15.6)

2.044 (0.400–10.457)

0.390

  1. aFirst-line regimen includes tenofovir, lamivudine and efavirenz; Second-line regimen includes tenofovir, lamivudine and lopinavir/ritonavir
  2. bOR, odds ratio; CI, confidential interval